ABBOTT LABORATORIES

ABT 10-K · FY 2025
API behind this page

ABT FY 2025 request

Playground key active
Request URL /api/financials?ticker=ABT&year=2025&quarter=4&full_year_mode=true
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric FY 2025 FY 2024 YoY
Revenue 44,328 41,950 +5.7%
Show Product Lines breakouts
COVID-19 Testing · Diagnostics 297 747 -60.2%
Show Business Segments breakouts
Diagnostics · Core Laboratory 5,360 5,235 +2.4%
Diagnostics · Molecular 517 521 -0.8%
Diagnostics · Non Us 5,402 5,511 -2.0%
Diagnostics · Non Us 3,935 3,903 +0.8%
Diagnostics · Non Us 367 371 -1.1%
Diagnostics · Non Us 184 180 +2.2%
Diagnostics · Non Us 916 1,057 -13.3%
Diagnostics · Operating Segments 8,937 9,341 -4.3%
Diagnostics · Point of Care 606 588 +3.1%
Diagnostics · Rapid Diagnostics 2,454 2,997 -18.1%
Diagnostics · US 3,535 3,830 -7.7%
Diagnostics · US 1,425 1,332 +7.0%
Diagnostics · US 150 150 0.0%
Diagnostics · US 422 408 +3.4%
Diagnostics · US 1,538 1,940 -20.7%
Established Pharmaceuticals · Key Emerging Markets 4,167 3,858 +8.0%
Established Pharmaceuticals · Non Us 5,536 5,194 +6.6%
Established Pharmaceuticals · Non Us 4,167 3,858 +8.0%
Established Pharmaceuticals · Non Us 1,369 1,336 +2.5%
Established Pharmaceuticals · Operating Segments 5,536 5,194 +6.6%
Established Pharmaceuticals · Other 1,369 1,336 +2.5%
Medical Devices · Diabetes Care 7,998 6,805 +17.5%
Medical Devices · Electrophysiology 2,764 2,467 +12.0%
Medical Devices · Heart Failure 1,448 1,279 +13.2%
Medical Devices · Neuromodulation 1,010 962 +5.0%
Medical Devices · Non Us 11,419 10,198 +12.0%
Medical Devices · Non Us 4,817 4,172 +15.5%
Medical Devices · Non Us 1,481 1,326 +11.7%
Medical Devices · Non Us 341 293 +16.4%
Medical Devices · Non Us 237 195 +21.5%
Medical Devices · Non Us 1,315 1,236 +6.4%
Medical Devices · Non Us 1,351 1,195 +13.1%
Medical Devices · Non Us 1,877 1,781 +5.4%
Medical Devices · Operating Segments 21,387 18,986 +12.6%
Medical Devices · Rhythm Management 2,649 2,390 +10.8%
Medical Devices · Structural Heart 2,523 2,246 +12.3%
Medical Devices · US 9,968 8,788 +13.4%
Medical Devices · US 3,181 2,633 +20.8%
Medical Devices · US 1,283 1,141 +12.4%
Medical Devices · US 1,107 986 +12.3%
Medical Devices · US 773 767 +0.8%
Medical Devices · US 1,334 1,154 +15.6%
Medical Devices · US 1,172 1,051 +11.5%
Medical Devices · US 1,118 1,056 +5.9%
Medical Devices · Vascular 2,995 2,837 +5.6%
Nutritionals · Adult Nutritionals 4,477 4,390 +2.0%
Nutritionals · Non Us 4,845 4,724 +2.6%
Nutritionals · Non Us 3,029 2,909 +4.1%
Nutritionals · Non Us 1,816 1,815 +0.1%
Nutritionals · Operating Segments 8,451 8,413 +0.5%
Nutritionals · Pediatric Nutritionals 3,974 4,023 -1.2%
Nutritionals · US 3,606 3,689 -2.2%
Nutritionals · US 1,448 1,481 -2.2%
Nutritionals · US 2,158 2,208 -2.3%
Show Geography breakouts
All Other Countries 15,979 14,786 +8.1%
CH 1,871 1,747 +7.1%
CN 1,907 2,113 -9.7%
DE 2,759 2,539 +8.7%
GB 1,340 1,185 +13.1%
IN 1,871 1,817 +3.0%
JP 1,475 1,441 +2.4%
Non Us 27,202 25,627 +6.1%
US 17,126 16,323 +4.9%
US · Corporate Non Segment 17 16 +6.2%
Show Consolidation Items breakouts
Corporate Non Segment 17 16 +6.2%
Operating Segments 44,311 41,934 +5.7%
Cost of Revenue 19,319 18,706 +3.3%
Show Business Segments breakouts
Diagnostics · Operating Segments -4,984 -4,995 +0.2%
Established Pharmaceuticals · Operating Segments -2,615 -2,444 -7.0%
Medical Devices · Operating Segments -6,973 -6,408 -8.8%
Nutritionals · Operating Segments -4,569 -4,532 -0.8%
Show Consolidation Items breakouts
Operating Segments -19,141 -18,379 -4.1%
Total Costs & Expenses 36,275 35,125 +3.3%
Research & Development 2,942 2,844 +3.4%
Show Business Segments breakouts
Diagnostics · Operating Segments 602 656 -8.2%
Established Pharmaceuticals · Operating Segments 176 176 0.0%
Medical Devices · Operating Segments 1,753 1,546 +13.4%
Nutritionals · Operating Segments 213 209 +1.9%
Show Consolidation Items breakouts
Operating Segments 2,744 2,587 +6.1%
Selling, General & Administrative 12,332 11,697 +5.4%
Show Business Segments breakouts
Diagnostics · Operating Segments 1,611 1,617 -0.4%
Established Pharmaceuticals · Operating Segments 1,455 1,341 +8.5%
Medical Devices · Operating Segments 5,449 4,879 +11.7%
Nutritionals · Operating Segments 2,111 2,167 -2.6%
Show Consolidation Items breakouts
Operating Segments 10,626 10,004 +6.2%
Operating Income 8,053 6,825 +18.0%
Show Business Segments breakouts
Diagnostics · Operating Segments 1,740 2,073 -16.1%
Established Pharmaceuticals · Operating Segments 1,290 1,233 +4.6%
Medical Devices · Operating Segments 7,212 6,153 +17.2%
Nutritionals · Operating Segments 1,558 1,505 +3.5%
Show Consolidation Items breakouts
Operating Segments 11,800 10,964 +7.6%
Interest Expense 493 559 -11.8%
Interest Income -308 -344 +10.5%
Other Non-Operating Income (Expense) -548 -376 -45.7%
Income Before Taxes 8,466 7,013 +20.7%
Income Tax Expense (Benefit) 1,942 -6,389 +130.4%
Net Income 6,524 13,402 -51.3%
Show Equity Components breakouts
Retained Earnings 6,524 13,402 -51.3%
Comprehensive Income 8,429 13,335 -36.8%
Other Comprehensive Income 1,905 -67 +2943.3%
Show Equity Components breakouts
Accumulated Defined Benefit Plans Adjustment 610 765 -20.3%
Accumulated Gain Loss Net Cash Flow Hedge Parent -279 169 -265.1%
Accumulated Other Comprehensive Income 1,905 -67 +2943.3%
Accumulated Translation Adjustment 1,574 -1,001 +257.2%
EPS (Basic) 3.73 7.67 -51.4%
EPS (Diluted) 3.72 7.64 -51.3%
Wtd Avg Shares (Basic) 1,741 1,740 +0.1%
Wtd Avg Shares (Diluted) 1,748 1,748 0.0%
Foreign Currency Transaction Gain Loss Before Tax -50 -27 -85.2%
Net Income Loss Available To Common Stockholders Basic 6.5 13.4 -51.5%

Balance Sheet

Balance Sheet
Metric FY 2025 FY 2024 YoY
Current Assets
Cash & Cash Equivalents 8,522 7,616 +11.9%
Short-Term Investments 417 351 +18.8%
Accounts Receivable 7,929 6,925 +14.5%
Inventory 6,488 6,194 +4.7%
Total Current Assets 25,996 23,656 +9.9%
Non-Current Assets
Property, Plant & Equipment 11,816 10,658 +10.9%
Operating Lease Right-of-Use Assets 1,126 1,075 +4.7%
Goodwill 24,035 23,108 +4.0%
Show Business Segments breakouts
Diagnostics 3.6 — —
Established Pharmaceuticals 2.7 — —
Medical Devices 17.4 — —
Nutritionals 285 — —
Total Assets 86,713 81,414 +6.5%
Show Business Segments breakouts
Diagnostics · Operating Segments 8,273 7,678 +7.7%
Established Pharmaceuticals · Operating Segments 3,540 3,087 +14.7%
Medical Devices · Operating Segments 10,689 9,472 +12.8%
Nutritionals · Operating Segments 4,791 4,404 +8.8%
Show Consolidation Items breakouts
Operating Segments 27,293 24,641 +10.8%
Long Term Investments 918 886 +3.6%
Show Fair Value By Measurement Basis breakouts
Carrying Reported Amount Fair Value Disclosure · Equity Securities 597 553 +8.0%
Carrying Reported Amount Fair Value Disclosure · Other Aggregated Investments 321 333 -3.6%
Estimate Of Fair Value Fair Value Disclosure · Equity Securities 597 553 +8.0%
Estimate Of Fair Value Fair Value Disclosure · Other Aggregated Investments 321 333 -3.6%
Show Investment Type breakouts
Equity Securities 597 553 +8.0%
Other Investments 321 333 -3.6%
Current Liabilities
Current Portion of Long-Term Debt 3,033 1,500 +102.2%
Total Current Liabilities 16,496 14,157 +16.5%
Non-Current Liabilities
Long-Term Debt 9,896 12,625 -21.6%
Long-Term Debt 12,929 14,125 -8.5%
Show Fair Value By Measurement Basis breakouts
Carrying Reported Amount Fair Value Disclosure 12,929 14,125 -8.5%
Estimate Of Fair Value Fair Value Disclosure 12,772 13,710 -6.8%
Operating Lease Liabilities 931 896 +3.9%
Other Non-Current Liabilities 2,538 2,586 -1.9%
Stockholders' Equity
Common Stock 25,527 25,153 +1.5%
Retained Earnings 49,781 47,261 +5.3%
Accumulated Other Comprehensive Income -6,001 -7,906 +24.1%
Total Stockholders' Equity 52,130 47,664 +9.4%
Total Liabilities & Equity 86,713 81,414 +6.5%

Cash Flow Statement

Cash Flow Statement
Metric FY 2025 FY 2024 YoY
Operating Activities
Stock-Based Compensation 664 673 -1.3%
Deferred Income Taxes 441 -7,961 +105.5%
Change in Accounts Receivable -652 -691 +5.6%
Change in Inventory 195 -58 +436.2%
Change in Prepaid & Other Assets -1,295 -796 -62.7%
Net Cash from Operations 9,566 8,558 +11.8%
Investing Activities
Capital Expenditures -2,171 -2,207 +1.6%
Other Investing Activities 18 9 +100.0%
Net Cash from Investing -2,422 -2,338 -3.6%
Financing Activities
Share Repurchases -893 -1,295 +31.0%
Net Cash from Financing -6,309 -5,404 -16.7%
Supplemental
Income Taxes Paid 1,933 1,723 +12.2%
Interest Paid 545 604 -9.8%
Other Cash Flow
Net Change in Cash 906 720 +25.8%

Values in millions USD. Source: SEC EDGAR 10-K filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key